Tipifarnib was observed as inhibiting PD-L1 protein expression more effectively in SR than SS RCC cells (Figure 6C) after testing the role of tipifarnib for PD-L1 expression in Caki-2-SS and Caki-2-SR cells. The gene discussed is CD274; the disease is renal cell carcinoma.